Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Extracapsular spread and adjuvant therapy in human papillomavirus‐related, p16‐positive oropharyngeal carcinoma

Open access
Sinha, Parul, Lewis, James S., Piccirillo, Jay F., Kallogjeri, Dorina, Haughey, Bruce H.·2012·Cancer

Abstract

BACKGROUND: Extracapsular spread (ECS) is commonly used to justify adjuvant chemotherapy in patients with head and neck cancer. The role of ECS as a prognosticator and adjuvant therapy determinant in surgically resected, human papillomavirus‐related oropharyngeal squamous cell carcinoma (OPSCC), however, has never been determined. METHODS: Of 210 oropharynx patients in a prospective transoral laser microsurgery database, 152 patients who had p16‐positive primary OPSCC and pathologically positive necks were eligible for the study. ECS was measured from routine reporting (ECS report) and by using a novel histologic grading system (ECS graded). Proportional hazards models and matched analyses were used to compare the impact of ECS and adjuvant therapy on disease‐free survival (DFS). Patients with and without graded ECS were matched for T‐stage, surgical margins, and adjuvant therapy. RESULTS: At a median follow‐up of 43 months, the presence of ECS was not associated with poorer DFS in multivariate analyses (ECS report: hazard ratio [HR], 3.42; 95% confidence interval [CI], 0.45‐25.88; P = .23; ECS graded: HR, 2.54; 95% CI, 0.88‐7.34; P = .09). T‐stage and high‐grade ECS, ie soft tissue metastasis (STM graded) were prognostic. Overall and in the presence of ECS or even STM, adjuvant CRT was not associated with better DFS over radiotherapy alone (HR, 0.25; 95% CI, 0.06‐1.13; P = .07). In addition, matched analyses demonstrated no significant reduction in DFS for the presence of ECS versus the absence of ECS or reduced DFS for the administration of adjuvant radiotherapy alone versus CRT in ECS‐positive patients. CONCLUSIONS: Routinely reported ECS was not prognostic in this study. Adjuvant CRT versus radiotherapy alone produced no improvement in DFS for ECS‐positive patients. The authors propose that de‐escalated adjuvant therapy should be considered for patients with p16‐positive OPSCC who undergo surgery and that routinely reported ECS should not be used to justify adjuvant chemotherapy. Cancer 2012;3519–3530. © 2011 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26671

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 246

Metadata

Authors
Sinha, P., Lewis, J. S., Piccirillo, J. F., Kallogjeri, D., & Haughey, B. H.
Venue
Cancer
Publisher
Wiley
Published
2011-11-15
Volume
118
Issue
14
Pages
3519-3530
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1591118513
Cited by
246
References
1
FWCI
8.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracapsular spread and adjuvant therapy in human papillomavirus‐related, p16‐positive oropharyngeal carcinoma. https://app.cochat.ai/papers/10.1002/cncr.26671
The paper
Sinha, P., Lewis, J. S., Piccirillo, J. F., Kallogjeri, D., & Haughey, B. H. (2012). Extracapsular spread and adjuvant therapy in human papillomavirus‐related, p16‐positive oropharyngeal carcinoma. Cancer. https://doi.org/10.1002/cncr.26671

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.